Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
08:33:48 EDT Sat 04 May 2024
Enter Symbol
or Name
USA
CA



News for U:BMRN from 2023-05-04 to 2024-05-03 - 26 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2024-04-24 16:03U:BMRNNews ReleaseBioMarin Reports Record Financial Results for the First Quarter 2024
2024-04-10 08:00U:BMRNNews ReleaseBioMarin to Host First Quarter 2024 Financial Results Conference Call and Webcast on Wednesday, April 24, 2024, at 4:30pm ET
2024-03-12 08:30U:BMRNNews ReleaseNew Data to be Presented for BioMarin's VOXZOGO(TM) (vosoritide) in Children with Hypochondroplasia and Achondroplasia at the American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting
2024-03-07 08:30U:BMRNNews ReleaseBioMarin Announces Appointment of Cristin Hubbard as Chief Commercial Officer
2024-03-01 09:00U:BMRNNews ReleaseBioMarin Scheduled to Participate in March Investor Conferences
2024-02-22 16:03U:BMRNNews ReleaseBioMarin Reports Record Financial Results for the Fourth Quarter and Full-year 2023 and Provides Financial Guidance for 2024
2024-02-08 08:00U:BMRNNews ReleaseBioMarin to Host Fourth Quarter and Full-Year 2023 Financial Results Conference Call and Webcast on Thursday, February 22, 2024, at 4:30pm ET
2024-02-06 08:30U:BMRNNews ReleaseBioMarin to Present ROCTAVIAN ¢ „ ¢ (valoctocogene roxaparvovec-rvox) Data Highlighting Long-Term Durability at 2024 European Association for Haemophilia and Allied Disorders (EAHAD) Congress
2024-01-03 08:00U:BMRNNews ReleaseBioMarin to Present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, at 10:30 am PT / 1:30 pm ET, in San Francisco, CA
2023-12-20 16:05U:BMRNNews ReleaseBioMarin Announces Governance Enhancements and Value Creation Initiatives
2023-11-28 08:30U:BMRNNews ReleaseBioMarin Announces Agreement with German Health Insurance Fund on Reimbursement Amount for ROCTAVIAN ‚ ® (valoctocogene roxaparvovec-rvox) for Severe Hemophilia A in Germany
2023-11-01 16:05U:BMRNNews ReleaseBioMarin Announces Strong Third Quarter 2023 Results, Including Continued Profitability, and 15% Total Revenue Growth Year Over Year
2023-11-01 16:02U:BMRNNews ReleaseBioMarin Announces Retirement of Jean-Jacques Bienaim ƒ ©; Appoints Alexander Hardy President and Chief Executive Officer
2023-10-20 16:05U:BMRNNews ReleaseU.S. Food and Drug Administration Approves BioMarin's VOXZOGO ‚ ® (vosoritide) for Children Under 5 Years with Achondroplasia
2023-10-17 08:30U:BMRNNews ReleaseBioMarin to Host Third-Quarter 2023 Financial Results Conference Call and Webcast on Wednesday, November 1, at 4:30pm ET
2023-09-21 10:00U:BMRNNews ReleaseBioMarin to Present Data Showing Long-Term Benefit of VOXZOGO ‚ ® (vosoritide) on Growth in Children with Achondroplasia at 2023 European Society for Paediatric Endocrinology (ESPE) Meeting
2023-09-15 09:29U:BMRNNews ReleaseBioMarin Receives Positive CHMP Opinion in Europe to Expand Use of VOXZOGO ‚ ® (vosoritide) to Treat Children Aged 4 Months and Older with Achondroplasia
2023-09-11 08:30U:BMRNNews ReleaseBioMarin to Present Innovative Pipeline at R&D Day on September 12th in New York
2023-09-06 08:30U:BMRNNews ReleaseBioMarin to Present Pipeline at Upcoming R&D Day on Tuesday, September 12th
2023-09-05 08:30U:BMRNNews ReleaseBioMarin to Participate in Three Upcoming Investor Conferences
2023-08-30 16:05U:BMRNNews ReleaseBioMarin Announces First Person Treated Commercially with ROCTAVIAN ‚ ® (valoctocogene roxaparvovec-rvox) for Severe Hemophilia A in Europe
2023-07-31 16:03U:BMRNNews ReleaseBioMarin Announces Strong Second Quarter 2023 Results and Record Breaking Revenues for the First Half of 2023, Including 13% Year Over Year Growth Year-to-date
2023-07-12 09:27U:BMRNNews ReleaseBioMarin to Host Second-Quarter 2023 Financial Results Conference Call and Webcast on Monday, July 31, at 4:30pm ET
2023-06-29 14:34U:BMRNNews ReleaseU.S. Food and Drug Administration Approves BioMarin's ROCTAVIAN ¢ „ ¢ (valoctocogene roxaparvovec-rvox), the First and Only Gene Therapy for Adults with Severe Hemophilia A
2023-06-22 08:00U:BMRNNews ReleaseBioMarin to Present ROCTAVIAN ¢ „ ¢ (valoctocogene roxaparvovec) Data from Longest and Largest Hemophilia Gene Therapy Clinical Trial Program at the International Society on Thrombosis and Haemostasis (ISTH) 2023 Congress
2023-05-04 16:01U:BMRNNews ReleaseBioMarin to Participate in Bank of America 2023 Health Care Conference